Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-12-02
1999-11-09
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514280, 546 48, C07D49114, C07D49122, C07D47104, A61K 3147
Patent
active
059815426
DESCRIPTION:
BRIEF SUMMARY
Camptothecin is a natural compound that was isolated for the first time from the leaves and the bark of the Chinese plant called camptotheca acuminata (see Wall et al., J. Amer. Chem. Soc. 88: 3888 (1966)). Camptothecin is a pentacyclic compound comprised of an indolizino [1,2-b] quinoline fragment fused with a six chained .alpha.-hydroxylactone. The carbon in position 20, which carries the .alpha.-hydroxy, is asymmetric and confers a rotational capacity to the molecule. The natural form of camptothecin possesses the absolute "S" configuration to the carbon 20 and complies with the following formula: ##STR2## Camptothecin presents an anti-proliferating activity in several cancerous cellular lines, comprising the cellular lines of human tumors of the colon, of the lung and of the breast (Suffness, M. et al., The Alkaloids Chemistry and Pharmacology, Bross, A., ed., Vol. 25, p. 73 (Academic Press, 1985)). It is suggested that the anti-proliferating activity of camptothecin is in relation to its inhibiting activity of topoisomerase I of DNA.
It was indicated that the .alpha.-hydroxylactone was an absolute necessity both for in vivo and in vitro activity of the camptothecin (Camptothecins: New Anticancer Agents, Putmesil, M. et al., ed., p. 27 (CRC Press. 1995); Wall, M. et al., Cancer Res. 55: 753 (1995); Hertzberg et al., J. Med. Chem. 32: 715 (1982) and Crow et al., J. Med. Chem. 35: 160 (1992)). The present invention concerns a new class of camptothecin compounds, in which a .beta.-hydroxylactone replaces the natural .alpha.-hydroxylactone of the camptothecin. The compounds according to the present invention exhibit powerful biological activity which is unexpected with respect to prior art.
Thus the invention has as its object new compounds of camptothecin which differ from all known compounds of camptothecin, in the sense that they contain a .beta.-hydroxylactone (or its open hydroxycarboxylic form) in place of an .alpha.-hydroxylactone (or its open hydroxycarboxylic form); or a pharmaceutically acceptable salt of the latter. By compound of camptothecin it is understood a compound presenting the same structural skeleton as that of camptothecin (that is to say an indolizino [1,2-b] quinoline fragment that is fused to a six chained .alpha.-hydroxylactone), with or without other chemical substitutions on the skeletal structure (for example the camptothecin compounds). Different camptothecin compounds are well known by specialists, as described below. By .beta.-hydroxylactone is meant a lactone that is comprised of a supplementary carbon atom between the carbon of the carboxyl and the .alpha.-carbon carrying the hydroxy group on the .alpha.-hydroxylactone. The .beta.-hydroxylactone of seven "closed" or "open" chains, in which the ester bond between the carbonyl group and the adjacent oxygen atom is hydrolized, which shows by the formation of a carboxylic acid group and a hydroxyl group, which groups may or may not be substituted.
A compound of camptothecin according to the invention may then comprise substitutions on the indolizino [1,2-5] quinoline fragment (for example to improve the solubility of the compound) or on the open or closed .beta.-hydroxylactone (for example to improve the stability of the compound). The examples of substitutions on closed .beta.-hydroxylactone are comprised of an alkyl substitution (for example ethyl) on the .beta.-carbon. The examples of substitution on the open .beta.-hydroxylactone are comprised of an alkyl substitution on the .beta.-carbon, substitutions (for example an amidation) on the carboxylic acid result, and the substitutions (for example an esterification) or suppressions of a hydroxyl group result.
The invention has more particularly for subject matter compounds of formula (I) and of formula (II), ##STR3## in racemic form, enantiomer or any combination of these forms, in which R.sub.1 represents a lower alkyl, a lower alkenyl, a lower alkynyl, a lower haloalkyl, and lower alkoxy lower alkyl or a lower alkylthio lower alkyl; alkyl, lower alkyl, lower alkenyl, cyano,
REFERENCES:
Journal of Medicinal Chemistry, vol. 32, No. 3, 1989 pp. 715-720.
Journal of Medicinal Chemistry, vol. 19, No. 5, May 1976 pp. 675-679.
Bigg Dennis
Lavergne Olivier
Pla Rodas Francesc
Pommier Jacques
Ulibarri Gerard
Kifle Bruck
Shah Mukund J.
Societe de Conseils de Recherches et d'Applications Scientifique
LandOfFree
Camptothecin analogues, preparation methods therefor, use thereo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Camptothecin analogues, preparation methods therefor, use thereo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Camptothecin analogues, preparation methods therefor, use thereo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456391